CD8 alpha Blocking Peptide for STJ505971 peptide (STJ505746)
SPECIFICATIONS
ImmunogenSynthetic peptide taken within amino acid region 1-50 on human T-cell surface glycoprotein CD8 Alpha chain.
General Information
| Short Description | CD8 alpha Blocking Peptide for STJ505971 is synthetically produced from the 1-50 sequence and is suitable for use in western blot applications. |
| Applications | Immunodepletion/Immunocompetition |
| Note | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Product Properties
| Formulation | Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction | Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
Target Information
| Gene Symbol | CD8A |
| Gene ID | 925 |
| Uniprot ID | CD8A_HUMAN |
| Immunogen | Synthetic peptide taken within amino acid region 1-50 on human T-cell surface glycoprotein CD8 Alpha chain. |
| Immunogen Region | 1-50 |
| Specificity | This blocking peptide is recommended for use in combination with CD8 alpha antibody, STJ505971 |
Additional Info
| Post Translational Modifications | Palmitoylated, but association with CD8B seems to be more important for the enrichment of CD8A in lipid rafts. O-glycosylated. Phosphorylated in cytotoxic T-lymphocytes (CTLs) following activation. |
| Function | Integral membrane glycoprotein that plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, functions primarily as a coreceptor for MHC class I molecule:peptide complex. The antigens presented by class I peptides are derived from cytosolic proteins while class II derived from extracellular proteins. Interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells (APCs). In turn, recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex. LCK then initiates different intracellular signaling pathways by phosphorylating various substrates ultimately leading to lymphokine production, motility, adhesion and activation of cytotoxic T-lymphocytes (CTLs). This mechanism enables CTLs to recognize and eliminate infected cells and tumor cells. In NK-cells, the presence of CD8A homodimers at the cell surface provides a survival mechanism allowing conjugation and lysis of multiple target cells. CD8A homodimer molecules also promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells. |
| Peptide Name | T-Cell Surface Glycoprotein Cd8 Alpha ChainT-Lymphocyte Differentiation Antigen T8/Leu-2Cd Antigen Cd8a |
| Database Links | Reactome: R-HSA-198933 |
| Cellular Localisation | Isoform 1: Cell MembraneSingle-Pass Type I Membrane ProteinCd8a Localizes To Lipid Rafts Only When Associated With Its Partner Cd8bIsoform 2: Secreted |
| Alternative Peptide Names | T-Cell Surface Glycoprotein Cd8 Alpha Chain proteinT-Lymphocyte Differentiation Antigen T8/Leu-2 proteinCd Antigen Cd8a proteinCD8A proteinMAL protein |
Information sourced from Uniprot.org